NPCE (NeuroPace) Cyclically Adjusted PS Ratio: (As of Jul. 05, 2026)


NPCE NeuroPace Inc NPCE
68 GF Score
Price $16.17
GF Value $11.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NeuroPace Cyclically Adjusted PS Ratio?

NeuroPace does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuroPace  (NAS:NPCE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


NeuroPace Cyclically Adjusted PS Ratio Related Terms


NeuroPace Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for NeuroPace's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroPace Cyclically Adjusted PS Ratio Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroPace Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NPCE vs CLPT, CTKB, CERS: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, NeuroPace's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeuroPace's Cyclically Adjusted PS Ratio falls into.


NPCE
68GF Score
NeuroPace Inc NPCE
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroPace Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

NeuroPace does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $16.17 is trading 41.7% above its estimated GF Value™ of $11.41. GuruFocus considers NeuroPace to be Significantly Overvalued.

Key valuation signals for NPCE:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $11.41 vs. price of $16.17 (41.7% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
68GF Score

Get the complete analysis for NPCE

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.17
Price
$11.41
GF Value